Pulmonx Stock Price, News & Analysis (NASDAQ:LUNG) $10.90 -0.13 (-1.18%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$10.81▼$11.1550-Day Range$7.89▼$11.0952-Week Range$5.30▼$14.27Volume416,209 shsAverage Volume323,521 shsMarket Capitalization$417.58 millionP/E RatioN/ADividend YieldN/APrice Target$13.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Pulmonx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside21.9% Upside$13.29 Price TargetShort InterestBearish4.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingSelling Shares$208,622 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.65) to ($1.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 starsMedical Sector865th out of 949 stocksSurgical & Medical Instruments Industry88th out of 94 stocks 2.3 Analyst's Opinion Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.29, Pulmonx has a forecasted upside of 21.9% from its current price of $10.90.Amount of Analyst CoveragePulmonx has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.19% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Pulmonx has recently increased by 3.08%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUNG. Previous Next 1.8 News and Social Media Coverage News SentimentPulmonx has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pulmonx this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LUNG on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,622.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions88.09% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.65) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pulmonx Stock (NASDAQ:LUNG)Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.Read More LUNG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUNG Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Insider Sells $12,550.40 in StockNovember 21, 2023 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Receives Average Rating of "Moderate Buy" from AnalystsDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 15, 2023 | finance.yahoo.comPulmonx to Present at the Piper Sandler 35th Annual Healthcare ConferenceOctober 31, 2023 | finance.yahoo.comPulmonx Corporation (NASDAQ:LUNG) Q3 2023 Earnings Call TranscriptOctober 30, 2023 | marketwatch.comPulmonx Shares Climb 17% as it Raises FY GuidanceOctober 30, 2023 | finance.yahoo.comPulmonx Corp (LUNG) Reports Record Q3 2023 Financial ResultsOctober 30, 2023 | finance.yahoo.comPulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue EstimatesDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!October 30, 2023 | finance.yahoo.comPulmonx Reports Record Third Quarter 2023 Financial ResultsOctober 27, 2023 | benzinga.comPulmonx Earnings PreviewOctober 16, 2023 | finance.yahoo.comPulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023October 11, 2023 | finanznachrichten.dePulmonx Corporation: Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 RevenueOctober 10, 2023 | finance.yahoo.comPulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 RevenueOctober 5, 2023 | msn.comPulmonx (LUNG) Price Target Increased by 10.99% to 17.17September 25, 2023 | abcnews.go.comIowa Gov. Kim Reynolds says her husband has lung cancerSeptember 6, 2023 | nasdaq.comCraig-Hallum Initiates Coverage of Pulmonx (LUNG) with Buy RecommendationSeptember 5, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Pulmonx (LUNG), Omnicell (OMCL)August 4, 2023 | msn.comPiper Sandler Maintains Pulmonx (LUNG) Overweight RecommendationAugust 3, 2023 | markets.businessinsider.comPulmonx (LUNG) Receives a Sell from Bank of America SecuritiesAugust 2, 2023 | finance.yahoo.comPulmonx Reports Second Quarter 2023 Financial ResultsJuly 26, 2023 | finance.yahoo.comPulmonx to Present at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 17, 2023 | finance.yahoo.comPulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023July 11, 2023 | msn.comCitigroup Maintains Pulmonx (LUNG) Buy RecommendationJuly 11, 2023 | benzinga.comCitigroup Maintains Buy on Pulmonx, Raises Price Target to $16July 10, 2023 | finance.yahoo.comShareholders in Pulmonx (NASDAQ:LUNG) are in the red if they invested a year agoJune 23, 2023 | msn.comPulmonx: Entry To Japan Market Bullish For Zephyr Volumes (Rating Upgrade)See More Headlines Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees269Year FoundedN/APrice Target and Rating Average Stock Price Target$13.29 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+21.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,920,000.00 Net Margins-94.47% Pretax Margin-93.59% Return on Equity-43.93% Return on Assets-31.68% Debt Debt-to-Equity Ratio0.30 Current Ratio7.19 Quick Ratio6.41 Sales & Book Value Annual Sales$53.66 million Price / Sales7.78 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book3.32Miscellaneous Outstanding Shares38,310,000Free Float36,124,000Market Cap$417.58 million OptionableNot Optionable Beta0.48 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Glendon E. French (Age 61)CEO, President & Director Comp: $892.29kMr. David A. Lehman (Age 62)General Counsel & Secretary Comp: $571.59kMr. Geoffrey Beran Rose (Age 49)Chief Commercial Officer Comp: $560.28kMr. John B. McKune (Age 47)Interim CFO Mr. Sri RadhakrishnanChief Technical OfficerMs. Marcee M. Maroney (Age 53)Vice President of Marketing Sarah HuberVice President of Sales (U.S.)Ms. Lisa Paul (Age 59)Chief People Officer Mr. Jérôme ErathSenior VP & GM of Europe Middle-East & AfricaMore ExecutivesKey CompetitorsCVRxNASDAQ:CVRXOrthofix MedicalNASDAQ:OFIXSurmodicsNASDAQ:SRDXPulse BiosciencesNASDAQ:PLSEIRadimedNASDAQ:IRMDView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 6,843 shares on 11/30/2023Ownership: 0.059%Deutsche Bank AGSold 490,932 shares on 11/24/2023Ownership: 0.122%Geoffrey Beran RoseSold 1,184 sharesTotal: $12,550.40 ($10.60/share)Graham Capital Management L.P.Sold 1,384 shares on 11/22/2023Ownership: 0.026%Walleye Capital LLCBought 372,290 shares on 11/21/2023Ownership: 0.972%View All Insider TransactionsView All Institutional Transactions LUNG Stock Analysis - Frequently Asked Questions Should I buy or sell Pulmonx stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LUNG shares. View LUNG analyst ratings or view top-rated stocks. What is Pulmonx's stock price target for 2024? 7 equities research analysts have issued 12 month target prices for Pulmonx's shares. Their LUNG share price targets range from $8.00 to $18.00. On average, they predict the company's share price to reach $13.29 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price. View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts. How have LUNG shares performed in 2023? Pulmonx's stock was trading at $8.43 at the beginning of 2023. Since then, LUNG shares have increased by 29.3% and is now trading at $10.90. View the best growth stocks for 2023 here. When is Pulmonx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our LUNG earnings forecast. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) posted its quarterly earnings data on Monday, October, 30th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.06. The company had revenue of $17.67 million for the quarter, compared to analysts' expectations of $16.67 million. Pulmonx had a negative net margin of 94.47% and a negative trailing twelve-month return on equity of 43.93%. Pulmonx's revenue for the quarter was up 30.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.38) EPS. What guidance has Pulmonx issued on next quarter's earnings? Pulmonx updated its third quarter 2023 earnings guidance on Tuesday, October, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.60 million-$17.60 million, compared to the consensus revenue estimate of $16.31 million. When did Pulmonx IPO? (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Pulmonx's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (14.42%), Morgan Stanley (5.79%), FMR LLC (5.30%), Deerfield Management Company L.P. Series C (2.66%), Braidwell LP (2.58%) and Victory Capital Management Inc. (2.50%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, Richard Ferrari and Scientific Corp Boston. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:LUNG) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.